Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs

References

• Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J. (2002). Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. Clin Pharmacol Ther 71:186–195.
   PubMed Web of Science ®Google Scholar
• Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717–727.
   PubMed Web of Science ®Google Scholar
• Agerso H, Seiding Larsen L, Riis a, Lovgren U, Karlsson M O, Senderovitz T. (2004) Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol 58:352–358.
   PubMed Web of Science ®Google Scholar
• Aggarwal S. (2007). What’s fueling the biotech engine? Nat Biotechnol 25:1097–1104.
   PubMed Web of Science ®Google Scholar
• Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. (2005). Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534–2543.
   PubMed Web of Science ®Google Scholar
• Bachmann K. (1989). Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J Appl Toxicol 9:331–338.
   PubMedGoogle Scholar
• Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. (1999). Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397–420.
   PubMedGoogle Scholar
• Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. (1998). Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab’)2. Toxicol Appl Pharmacol 150:295–300.
   PubMed Web of Science ®Google Scholar
• Belpaire FM, de Smet F, Vynckier LJ, Vermeulen AM, Rosseel MT, Bogaert MG, Chauvelot-Moachon L. (1990). Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat. J Pharmacol Exp Ther 254:116–122.
   PubMedGoogle Scholar
• Björkman S, Redke F. (2000). Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application to prediction of clearance in man. J Pharm Pharmacol 52:1065–1074.
   PubMed Web of Science ®Google Scholar
• Bleuel H, Hoffmann R, Kaufmann B, Neubert P, Ochlich PP, Schaumann W. (1996). Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice. Pharmacology 52:329–338.
   PubMed Web of Science ®Google Scholar
• Bolton, S. (1997) Pharmaceutical statistics: practical and clinical applications, New York, Marcel Dekker Inc.
   Google Scholar
• Bortolotti A, Castelli D, Verotta D, Bonati M. (1989). Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. Eur J Drug Metab Pharmacokinet 14:145–151.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227.
   PubMedGoogle Scholar
• Boxenbaum H, DiLea C. (1995). First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 35:957–966.
   PubMed Web of Science ®Google Scholar
• Braeckman, R. (2000) Pharmacokinetics and pharmacodynamics of protein therapeutics, CRC Press.
   Google Scholar
• Brocks DR, Freed MI, Martin DE, Sellers TS, Mehdi N, Citerone DR, Boppana V, Levitt B, Davies BE, Nemunaitis J, Jorkasky DK. (1996). Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. Pharm Res 13:794–797.
   PubMedGoogle Scholar
• Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–484.
   PubMed Web of Science ®Google Scholar
• Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. (2007). Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 62:43–52.
   PubMed Web of Science ®Google Scholar
• Cernacek P, Maher E, Crawhall JC, Levy M. (1988). Renal dose response and pharmacokinetics of atrial natriuretic factor in dogs. Am J Physiol 255:R929–R935.
   Google Scholar
• Chang T, Black A, Dunky A, Wolf R, Sedman A, Latts J, Welling PG. (1988). Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. J Antimicrob Chemother 21 Suppl B:49–56.
   PubMedGoogle Scholar
• Cohenuram M, Saif MW. (2007). Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18:7–15.
   PubMed Web of Science ®Google Scholar
• Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. (1991). Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 84:1216–1234.
   PubMedGoogle Scholar
• Crombet T, Torres O, Neninger E, Catalá M, Rodríguez N, Ramos M, Fernández E, Iznaga N, Pérez R, Lage A. (2001). Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 16:93–102.
   PubMed Web of Science ®Google Scholar
• Cruze CA, Kelm GR, Meredith MP. (1995). Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharm Res 12:895–901.
   PubMedGoogle Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes GR. (1995). Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 23:1028–1036.
   PubMed Web of Science ®Google Scholar
• Davis LE, Westfall BA. (1972). Species differences in biotransformation and excretion of salicylate. Am J Vet Res 33:1253–1262.
   PubMed Web of Science ®Google Scholar
• Dedrick R, Bischoff KB, Zaharko DS. (1970). Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95–101.
   PubMedGoogle Scholar
• Dedrick RL, Forrester DD, Cannon JN, el-Dareer SM, Mellett LB. (1973). Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. Biochem Pharmacol 22:2405–2417.
   PubMed Web of Science ®Google Scholar
• Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. (2001). Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41:1206–1214.
   PubMed Web of Science ®Google Scholar
• Doyle E, Chasseaud LF, Miller JN. (1982). Comparative pharmacokinetics of frusemide in female rhesus monkeys, cynomolgus monkeys and baboons. Comp Biochem Physiol C, Comp Pharmacol 71C:89–93.
   PubMedGoogle Scholar
• Egrie JC, Dwyer E, Dwyer E, Browne JK, Browne, JK, Hitz, A, Hitz A, Lykos MA, (2003). Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
   Google Scholar
• Eriksson UG, Renberg L, Bredberg U, Teger-Nilsson AC, Regårdh CG. (1998). Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. Biopharm Drug Dispos 19:55–64.
   PubMedGoogle Scholar
• Evans CA, Jolivette LJ, Nagilla R, Ward KW. (2006). Extrapolation of preclinical pharmacokinetics and molecular feature analysis of “discovery-like” molecules to predict human pharmacokinetics. Drug Metab Dispos 34:1255–1265.
   PubMed Web of Science ®Google Scholar
• Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK. (1996). The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 174:463–469.
   PubMed Web of Science ®Google Scholar
• Feldman HA, McMahon TA. (1983). The ¾ mass exponent for energy metabolism is not a statistical artifact. Respir Physiol 52:149–163.
   PubMedGoogle Scholar
• Feng MR, Loo J, Wright J. (1998). Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. Drug Metab Dispos 26:982–988.
   PubMedGoogle Scholar
• Feng MR, Lou X, Brown RR, Hutchaleelaha A. (2000). Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 17:410–418.
   PubMed Web of Science ®Google Scholar
• Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH. (1990). Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47:557–564.
   PubMed Web of Science ®Google Scholar
• Gatti G, Kahn JO, Lifson J, Williams R, Turin L, Volberding PA, Gambertoglio JG. (1991). Pharmacokinetics of GLQ223 in rats, monkeys, and patients with AIDS or AIDS-related complex. Antimicrob Agents Chemother 35:2531–2537.
   PubMedGoogle Scholar
• Geary RS, Yu RZ, Levin AA. (2001). Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2:562–573.
   PubMedGoogle Scholar
• Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA. (2003). Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2’-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 31:1419–1428.
   PubMed Web of Science ®Google Scholar
• Giachetti C, Bertolino M, Canali S, Lombardini E, Monzani MV, Sala A, Zanolo G. (1998). Pharmacokinetic study in dogs and monkeys after single intravenous and oral administrations of [14C]-ITF-296. Eur J Drug Metab Pharmacokinet 23:239–250.
   PubMedGoogle Scholar
• Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. (2009). Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 113:1062–1070.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. (2001). Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850.
   PubMed Web of Science ®Google Scholar
• Goteti K, Brassil PJ, Good SS, Garner CE. (2008). Estimation of human drug clearance using multiexponential techniques. J Clin Pharmacol 48:1226–1236.
   PubMed Web of Science ®Google Scholar
• Grene-Lerouge NA, Bazin-Redureau MI, Debray M, Scherrmann JM (1996). Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol 138:84–89.
   Google Scholar
• Guentert TW, Huang JD, Oie S. (1982). Disposition of quinidine in the rabbit. J Pharm Sci 71:812–815.
   PubMedGoogle Scholar
• Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA. (1991). Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50:702–712.
   PubMed Web of Science ®Google Scholar
• Harris PA, Gross JF. (1975). Preliminary pharmacokinetic model for adriamycin (NSC-123127). Cancer Chemother Rep 59:819–825.
   PubMedGoogle Scholar
• Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. (1989). The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 24 Suppl A:265–277.
   PubMedGoogle Scholar
• Hauptmann J. (2002). Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 57:751–758.
   PubMed Web of Science ®Google Scholar
• Hérault JP, Donat F, Bàrzu T, Crépon B, Bernat A, Lormeau JC, Herbert JM. (1997). Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. Blood Coagul Fibrinolysis 8:161–167.
   PubMedGoogle Scholar
• Higuchi S, Shiobara Y. (1980). Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica 10:447–454.
   PubMed Web of Science ®Google Scholar
• Hinderling PH, Dilea C, Koziol T, Millington G. (1993). Comparative kinetics of sematilide in four species. Drug Metab Dispos 21:662–669.
   PubMedGoogle Scholar
• Hirai J, Miyazaki H, Taneike T. (1992). The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. J Vet Pharmacol Ther 15:231–239.
   PubMedGoogle Scholar
• Ho M, Silamut K, White NJ, Karbwang J, Looareesuwan S, Phillips RE, Warrell DA. (1990). Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand. Am J Trop Med Hyg 42:260–266.
   PubMed Web of Science ®Google Scholar
• Hu T-M, Chiu S-J. (2009). Prediction of human drug clearance using a single-species, fixed-exponent allometric approach. Journal of Medical Sciences 29:331–339.
   Google Scholar
• Hu TM, Hayton WL. (2001). Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3:E29.
   PubMedGoogle Scholar
• Hutchaleelaha A, Chow HH, Mayersohn M. (1997). Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol 49:178–183.
   PubMedGoogle Scholar
• Iavarone L, Hoke JF, Bottacini M, Barnaby R, Preston GC. (1999). First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol 39:560–566.
   PubMed Web of Science ®Google Scholar
• Ishizuka M, Nagai S, Sakamoto KQ, Fujita S. (2007). Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. Xenobiotica 37:503–513.
   PubMed Web of Science ®Google Scholar
• Iven H. (1977). The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. Naunyn Schmiedebergs Arch Pharmacol 298:43–50.
   PubMedGoogle Scholar
• Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y. (1996). Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630–1641.
   PubMed Web of Science ®Google Scholar
• Kagan L, Abraham AK, Harrold JM, Mager DE. (2010). Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 27:920–932.
   PubMed Web of Science ®Google Scholar
• Kaul S, Dandekar KA, Schilling BE, Barbhaiya RH. (1999). Toxicokinetics of 2’,3’-didehydro-3’-deoxythymidine, stavudine (D4T). Drug Metab Dispos 27:1–12.
   PubMedGoogle Scholar
• Keith JC Jr, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L, Schaub RG. (1995). Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost 73:101–105.
   PubMed Web of Science ®Google Scholar
• Kenny JR, Grime K. (2006). Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. Xenobiotica 36:351–365.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim WB, Lee MG. (1998). Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 19:231–235.
   PubMed Web of Science ®Google Scholar
• Kleiber M. (1947). Body size and metabolic rate. Physiol Rev 27:511–541.
   PubMed Web of Science ®Google Scholar
• Krieter PA, Trapani AJ. (1989). Metabolism of atrial natriuretic peptide. Extraction by organs in the rat. Drug Metab Dispos 17:14–19.
   PubMedGoogle Scholar
• Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, Kawahara Y. (1992). Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data. Antimicrob Agents Chemother 36:1810–1816.
   PubMed Web of Science ®Google Scholar
• Kuwabara T, Kato Y, Kobayashi S, Suzuki H, Sugiyama Y. (1994). Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans. J Pharmacol Exp Ther 271:1535–1543.
   PubMed Web of Science ®Google Scholar
• Lai Y, Sampson KE, Balogh LM, Brayman TG, Cox SR, Adams WJ, Kumar V, Stevens JC. (2010). Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther 334:936–944.
   PubMed Web of Science ®Google Scholar
• Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. (1997). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584–590.
   PubMed Web of Science ®Google Scholar
• Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W, Chou RC. (1995). Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci 84:1285–1290.
   PubMedGoogle Scholar
• Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, Chou RC. (1996). Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 48:573–577.
   PubMedGoogle Scholar
• Lepist EI, Jusko WJ. (2004). Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Ther 27:211–218.
   PubMedGoogle Scholar
• Levin AA. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489:69–84.
   PubMed Web of Science ®Google Scholar
• Levin AA, Yu RZ, Geary RS. (2001). Basic principles of the pharmacokinetics of antisense oligonucleotide drugs, CRC Press.
   Google Scholar
• Lin JH. (2009). Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies. Curr Drug Metab 10:661–691.
   Google Scholar
• Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. (1999). Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371–378.
   PubMed Web of Science ®Google Scholar
• Ling J, Zhou H, Jiao Q, Davis HM. (2009). Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 49:1382–1402.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. (2004). Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645–2668.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B. (2006). Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1:1211–1215.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (1998). Interspecies scaling of renally secreted drugs. Life Sci 63:2365–2371.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2004). Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 93:177–185.
   PubMed Web of Science ®Google Scholar
• Mahmood I.(2005) Prediction of clearance using monkey liver blood flow, Rockville, Pine House Publishers.
   Google Scholar
• Mahmood I. (2009). Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 24:57–81.
   PubMedGoogle Scholar
• Mahmood I. (2009). Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 98:3850–3861.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
   PubMed Web of Science ®Google Scholar
• Marleau S, Ong H, De Léan A, du Souich P. (1989). Disposition and dynamics of atrial natriuretic factor in conscious rabbits. J Pharmacol Exp Ther 251:328–333.
   PubMedGoogle Scholar
• Martin U, Khler J, Sponer G, Strein K. (1992). Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates. Fibrinolysis 6:39–43.
   Google Scholar
• Martin U, von Möllendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. (1991). Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. Thromb Haemost 66:569–574.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Suzuki H, Sugiyama Y, Sawada Y, Iga T, Hanano M, Kawaguchi Y. (1990). Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J Pharmacobio-dyn 13:602–611.
   PubMedGoogle Scholar
• McCarthy K, Stewart P, Sigman J, Read M, Keith JC Jr, Brinkhous KM, Nichols TC, Schaub RG. (2002). Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 87:824–830.
   PubMed Web of Science ®Google Scholar
• Mellett LB. (1969). Comparative drug metabolism. Prog Drug Res 13:136–169.
   PubMedGoogle Scholar
• Monzani MV, Coltro G, Jiritano L, Sala A. (1995). Pharmacokinetic profile of ITF 296 in rats and dogs. J Cardiovasc Pharmacol 26 Suppl 4:S67–S71.
   Google Scholar
• Monzani MV, Coltro G, Sala A, Sardina M. (1999). Pharmacokinetics of ITF 296 (Sinitrodil) a novel organic nitrate, in healthy volunteers. Eur J Pharm Sci 7:179–184.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. (1991). Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351–1359.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. (1996). Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 136:75–78.
   PubMedGoogle Scholar
• Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. (2009). Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J Clin Oncol 27:3346–3353.
   PubMed Web of Science ®Google Scholar
• Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, Cho DK. (1987). Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab Dispos 15:618–626.
   PubMed Web of Science ®Google Scholar
• Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC. (2007). Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13:2128–2135.
   PubMed Web of Science ®Google Scholar
• Murthy SS, Nelson WL, Shen DD, Power JM, Cahill CM, McLean AJ. (1991). Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. Drug Metab Dispos 19:1093–1100.
   PubMedGoogle Scholar
• Nagilla R, Ward KW. (2004). A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 93:2522–2534.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Koyama M, Matsui H, Ikeda C, Yano K, Nakatsuru N, Yoshinaga K, Noguchi T. (1984). Pharmacokinetics of cefpiramide (SM-1652) in humans. Antimicrob Agents Chemother 25:221–225.
   PubMedGoogle Scholar
• Nakamura S, Kurobe N, Kashimoto S, Ohue T, Takase Y, Shimizu M. (1983). Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother 24:54–60.
   PubMedGoogle Scholar
• Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM. (2004). Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res 10:2525–2529.
   PubMed Web of Science ®Google Scholar
• Nouws JF, Mevius DJ, Vree TB, Baars AM, Laurensen J. (1988). Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. Vet Q 10:156–163.
   PubMed Web of Science ®Google Scholar
• Nowak G. (1991). Pharmacokinetics of hirudin. Semin Thromb Hemost 17:145–149.
   PubMed Web of Science ®Google Scholar
• Obach RS, Lombardo F, Waters NJ. (2008). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–1405.
   PubMed Web of Science ®Google Scholar
• Ohdo S, Arata N, Furukubo T, Yukawa E, Higuchi S, Nakano S, Ogawa N. (1998). Chronopharmacology of granulocyte colony-stimulating factor in mice. J Pharmacol Exp Ther 285:242–246.
   PubMedGoogle Scholar
• Oikawa K, Kamimura H, Watanabe T, Miyamoto I, Higuchi S. (2001). Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Thromb Res 101:493–500.
   PubMed Web of Science ®Google Scholar
• Oikawa K, Watanabe T, Miyamoto I, Higuchi S. (2000). Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. Xenobiotica 30:993–1003.
   PubMed Web of Science ®Google Scholar
• Olsen KM, Martin SJ. (2002). Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis. Pharmacotherapy 22:196S–205S.
   Google Scholar
• Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JH. (2009). The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31–40.
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. (2009). Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 348:36–41.
   PubMed Web of Science ®Google Scholar
• Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. (2004). Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158–162.
   PubMed Web of Science ®Google Scholar
• Prandota J, Pruitt AW. (1991). Pharmacokinetic, biliary excretion, and metabolic studies of 14C-furosemide in the rat. Xenobiotica 21:725–736.
   PubMed Web of Science ®Google Scholar
• Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM. (2010). Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16:1652–1661.
   PubMedGoogle Scholar
• Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, Jusko WJ. (1998). Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res 15:1895–1901.
   PubMedGoogle Scholar
• Rane A, Högstedt S, Lindberg B, Regårdh CG, Jorulf H. (1984). Comparison of different clearance estimates for metoprolol in the rhesus monkey. J Pharmacol Exp Ther 228:774–778.
   PubMedGoogle Scholar
• Richter W F, Gallati H, Schiller C D. (1999). Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 27:21–25.
   PubMed Web of Science ®Google Scholar
• Richter WF, Heizmann P, Meyer J, Starke V, Lave T. (1998). Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. J Pharm Sci 87:496–500.
   PubMedGoogle Scholar
• Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. (1991). Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species. Methods Find Exp Clin Pharmacol 13:697–702.
   PubMedGoogle Scholar
• Robbie G, Chiou WL. (1998). Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm Res 15:1630–1636.
   PubMedGoogle Scholar
• Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, Graham MA, Geboes K, Rousselle SD, Wagner CL. (2005). Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313:578–585.
   PubMed Web of Science ®Google Scholar
• Sacher GA. (2008) Relation of Lifespan to Brain Weight and Body Weight in Mammals, John Wiley & Sons, Ltd.
   Google Scholar
• Sangalli L, Bortolotti A, Jiritano L, Bonati M. (1988). Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metab Dispos 16:749–753.
   PubMed Web of Science ®Google Scholar
• Sardina M, Love R, Mizrahi J, Monzani V, Bianchini C. (1995). Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers. J Cardiovasc Pharmacol 26 Suppl 4:S72–S79.
   Google Scholar
• Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA. (2002). Phase I trial of ISIS 104838, a 2’-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303:1334–1343.
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. (1999). A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52:1072–1074.
   PubMed Web of Science ®Google Scholar
• Siefert HM, Maruhn D, Scholl H. (1986). Pharmacokinetics of ciprofloxacin. 2nd communication: distribution to and elimination from tissues and organs following single or repeated administration of [14C]ciprofloxacin in albino rats. Arzneimittelforschung 36:1503–1510.
   PubMed Web of Science ®Google Scholar
• Srinivas NR, Shyu WC, Weiner RS, Warner G, Comereski C, Tay LK, Greene DS, Barbhaiya RH. (1997). Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. Pharm Res 14:911–916.
   PubMed Web of Science ®Google Scholar
• Srinivas NR, Weiner RS, Shyu WC, Calore JD, Tritschler D, Tay LK, Lee JS, Greene DS, Barbhaiya RH. (1996). A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice. J Pharm Sci 85:296–298.
   PubMed Web of Science ®Google Scholar
• Srinivas NR, Weiner RS, Warner G, Shyu WC, Davidson T, Fadrowski CG, Tay LK, Lee JS, Greene DS, Barbhaiya RH. (1996). Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J Pharm Sci 85:1–4.
   PubMed Web of Science ®Google Scholar
• Stokol T, Trepanier L, Parry BW, Finnin BC. (1997). Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A. Res Vet Sci 63:23–27.
   PubMedGoogle Scholar
• Tanaka E, Ishikawa A, Horie T. (1999). In vivo and in vitro trimethadione oxidation activity of the liver from various animal species including mouse, hamster, rat, rabbit, dog, monkey and human. Hum Exp Toxicol 18:12–16.
   PubMedGoogle Scholar
• Tang L, Persky AM, Hochhaus G, Meibohm B. (2004). Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93:2184–2204.
   PubMed Web of Science ®Google Scholar
• Tanswell P, Modi N, Combs D, Danays T. (2002). Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 41:1229–1245.
   PubMed Web of Science ®Google Scholar
• Tranum BL, Stephens RL, Lehane DE, Hoogstraten B, Lane M, Haut A. (1975). Adriamycin (NSC-123127) plus 5-fluorouracil (NSC-19893): a phase I study. Cancer Chemother Rep 59:1163–1165.
   PubMedGoogle Scholar
• Tsunekawa Y, Hasegawa T, Nadai M, Takagi K, Nabeshima T. (1992). Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. J Pharm Pharmacol 44:594–599.
   PubMedGoogle Scholar
• Ueda CT, Ballard B, Rowland M. (1977). Concentration-time effects of quinidine disposition kinetics in rhesus monkeys. J Pharmacol Exp Ther 200:459–468.
   PubMedGoogle Scholar
• Ujhelyi MR, Robert S. (1995). Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 28:483–493.
   PubMed Web of Science ®Google Scholar
• Valverde CR, Mama KR, Kollias-Baker C, Steffey EP, Baggot JD. (2000). Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). Am J Vet Res 61:931–934.
   PubMedGoogle Scholar
• Wang W, Prueksaritanont T. (2010). Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 31:253–263.
   PubMed Web of Science ®Google Scholar
• Ward KW, Smith BR. (2004). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603–611.
   PubMed Web of Science ®Google Scholar
• Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. (2003). Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25:1700–1721.
   PubMed Web of Science ®Google Scholar
• White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, Courter S. (1998). Clinical evaluation of recombinant factor IX. Semin Hematol 35:33–38.
   PubMed Web of Science ®Google Scholar
• Woo S, Jusko WJ. (2007). Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos 35:1672–1678.
   PubMed Web of Science ®Google Scholar
• Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. (1986). Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 38:1827–1833.
   PubMed Web of Science ®Google Scholar
• Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. (2007). Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35:460–468.
   PubMed Web of Science ®Google Scholar